Imfinzi significantly improved overall survival and progression-free survival for patients with…
Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in…
Read More...
Read More...